Nilaya Varma, Group CEO & Co-Founder, Primus Partners, highlights that innovations in drug delivery systems are driving the growth of needle-free injectors. With increasing concerns over needle-stick injuries, rising chronic diseases, and the growing demand for mass vaccinations and home care, the global needle-free injector market—valued at $1.3 billion in 2022—is projected to grow at a CAGR of 7.8%, with strong potential in both global and Indian markets.